Skip to content

Patient Preferences for Barrett's Esophagus and Esophageal Cancer Screening Tests

Patient Preferences for Barrett's Esophagus and Esophageal Cancer Screening Tests: A Discrete Choice-Based Conjoint Analysis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06693622
Enrollment
556
Registered
2024-11-18
Start date
2024-11-01
Completion date
2029-03-01
Last updated
2024-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastro Esophageal Reflux Disease, Barrett Esophagus

Keywords

Gastroesophageal Reflux Disease, Barrett's Esophagus, Barrett's Esophagus Screening, BE, GERD

Brief summary

This study plans to learn more about what patients think about screening for esophageal cancer (EAC) and Barrett's esophagus (BE); a pre-cancerous condition associated with esophageal cancer. The plan is to use this information to modify screening practices in the United States with the goal to decrease the number of people who die from esophageal cancer.

Detailed description

To achieve this goal, patient preferences for BE/EAC screening tests will be evaluated through a prospective multicenter discrete choice-based conjoint survey. Patients will choose between a series of hypothetical options and rank their priorities and what they value according to differences in benefit of detection (sensitivity), convenience (time, setting), screening related physical harms (procedural discomfort), and financial harms. By evaluating relative importance of test characteristics and patient prioritization the study will (1) define patient preferences and barriers for attributes of BE/EAC screening modalities to elicit the overall preferred test as well as differences in each attribute that informed that choice and (2) characterize differences in BE/EAC test preferences by patient sociodemographic characteristics (age, sex, race, ethnicity) and by the presence or absence of gastroesophageal reflux disease (GERD).

Interventions

BEHAVIORALPatient survey

To assess patient preferences and barriers for attributes of BE/EAC screening modalities patients will complete a survey evaluating 5 domains: benefit of detection (sensitivity), convenience (time, setting), screening related physical harms (procedural discomfort), and financial harms. Prior to distribution, the survey will be refined and pretested among a sample of 5 patients.

Sponsors

American Society for Gastrointestinal Endoscopy
CollaboratorOTHER
University of California, Los Angeles
CollaboratorOTHER
University of Michigan
CollaboratorOTHER
Exact Sciences Corporation
CollaboratorINDUSTRY
VA Medical Center-West Los Angeles
CollaboratorFED
University of Texas Southwestern Medical Center
CollaboratorOTHER
University of Colorado, Denver
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 89 Years
Healthy volunteers
Yes

Inclusion criteria

* Provision to sign and date the consent form. * Stated willingness to comply with all study procedures and be available for the duration of the study. * Individual has 3 or more established risk factors for BE (age \> 50 years, chronic GERD, male, white race, smoking, obesity, family history of BE/EAC).

Exclusion criteria

* Unable to consent. * Prior diagnosis of BE/EAC. * Life limiting comorbidity/ disability. * Active dementia/ cognitive impairment. * Incarcerated.

Design outcomes

Primary

MeasureTime frameDescription
Define patient preferred BE/EAC screening test and barriers for attributes of BE/EAC screening testsBaselineA discrete choice-based conjoint analysis survey evaluating 5 domains: benefit of detection (sensitivity), convenience (time, setting), screening related physical harms (procedural discomfort), and financial harms will be used to determine the relative importance of BE/EAC screening test characteristics and patient priorities. Survey data will be reported in aggregate and factors and choices will be analyzed using the Fisher Exact and Mann-Whitney rank-sum tests. This approach will elicit the overall preferred test and differences in each test attribute that informed the patients choice.

Secondary

MeasureTime frameDescription
Characterization of differences in BE/EAC test preferences by patient sociodemographic characteristics and by patient presence or absence of GERDBaselineUsing the discrete choice-based conjoint analysis survey analysis, a logistic regression model of patient-specific attributes (age, sex, race, ethnicity) and by presence or absence of GERD will be used to evaluate if disparities in patient demographics or heath history impact complex decision making.

Countries

United States

Contacts

Primary ContactAlexa DeBord, MS
alexa.debord@cuanschutz.edu303-724-0432

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026